FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns methods and compositions for inducing apoptosis of cancer cells. Substance of the invention includes the modified antibodies-DR-5 agonists which in combination with apoptosis-inducing agents, synergetically induce apoptosis of cancer cells.
EFFECT: intensified antineoplastic activity.
19 cl, 51 ex, 2 tbl, 35 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BORONIC ACID DERIVATIVES | 2018 |
|
RU2793315C2 |
| BETA-LACTAMASE INHIBITORS | 2015 |
|
RU2686740C2 |
| ANALYSES AND METHODS USING BIOMARKERS | 2005 |
|
RU2410438C2 |
| ANALYSES AND METHODS WITH APPLICATION OF BIOMARKERS | 2005 |
|
RU2431676C2 |
| APOPTOSIS DETECTION TECHNIQUES AND REAGENTS | 2007 |
|
RU2450273C2 |
| APOPTOTIC Apo2L/TRAIL SENSITIVITY BY TESTING GalNac-T14 EXPRESSION IN CELLS/TISSUES | 2006 |
|
RU2416097C2 |
| COMBINATION OF ANTIBODY HAVING SELECTIVITY IN RELATES TO APOPTOSIS INDUCING LIGAND RECEPTOR ASSOCIATED WITH TUMOR NECROSIS FACTOR AND OTHER THERAPEUTIC AGENTS | 2002 |
|
RU2313368C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| ANTIBODY SELECTIVE TO RECEPTOR APOPTOSIS-INDUCING LIGAND AND ASSOCIATED WITH TUMOR NECROSIS FACTOR AND ITS USING | 2002 |
|
RU2313537C2 |
| BORONIC ACID DERIVATIVES | 2015 |
|
RU2717558C2 |
